+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


A Global Hyperhidrosis Market Landscape Assessment: Trends, Forecasts and Opportunities in a Growing Market

  • ID: 4417646
  • Report
  • September 2017
  • Region: Global
  • 63 Pages
  • CBR Pharma Insights
1 of 3
Primary Axillary Hyperhidrosis Therapeutics Market for the Seven Major Markets is Expected to Grow to $680.7m by 2023, at a CAGR of 3.3%

Hyperhidrosis is a chronic disorder of excessive sweating beyond thermoregulatory needs and environmental conditions. It commonly arises in childhood and adolescence, and can affect patients for many years. Most cases of hyperhidrosis involve areas of high eccrine (sweat gland) density, particularly in the armpits, palms and soles, and less often in the facial area. According to the International Hyperhidrosis Society (IHS), the global prevalent population of hyperhidrosis is 367 million. The US has the most hyperhidrosis cases among the major developed countries covered in this report. Hyperhidrosis occurs in men and women equally, and can present at any age.

Primary axillary hyperhidrosis therapeutics market for the seven major markets is expected to grow to $680.7m by 2023, at a compound annual growth rate (CAGR) of 3.3%. This expected growth is due to increasing awareness of primary axillary hyperhidrosis as a treatable medical condition across the major developed markets, thus resulting in an increased diagnosis rate, and therefore a larger treatment-receiving population.

United States has the most hyperhidrosis cases amongst the major developed countries covered in this report. The reported prevalence rate for hyperhidrosis in the US is approximately 4.8%. Of these sufferers, 65% have axillary hyperhidrosis. In 2013, the reported prevalence rate for primary axillary hyperhidrosis in Japan was 5.75%, meaning nearly 2.23 million people suffered from severe symptoms of primary axillary hyperhidrosis. In 2016 the reported prevalence rate for primary focal hyperhidrosis in Germany was 4.6%. The reported prevalence rate for hyperhidrosis in the UK in 2005 stood at 1.62%. There are more than 1.2 million hyperhidrosis prevalent cases in Spain.

Allergan’s Botox is the only approved product to treat primary axillary hyperhidrosis. Botox’s major competitors are other botulinum toxin products such as Dysport and Xeomin, which are currently used off-label to treat the condition. Botox’s revenue in this indication is expected to decline over the period due to competition from existing off-label products, and an increasing preference for medical devices that can provide permanent treatment for the disease.

The report “A Global Hyperhidrosis Market Landscape Assessment: Trends, Forecasts and Opportunities in a Growing Market” provides an in-depth assessment of the current trends in the global hyperhidrosis market, with a particular focus on primary axillary hyperhidrosis. This report also assesses the commercial landscape through multilevel analytics that include data split by stage of development, molecular target, molecule type and route of administration.

Primary Axillary Hyperhidrosis in the Major Developed Markets will Show a Slight Increase in Growth Rate During the Forecast Period

  • How will the approved, late-stage and other off-label products contribute to market growth?
  • What will be the effect of approved medical devices on available drug therapies?

The Global Primary Axillary Hyperhidrosis Pipeline Lacks Novelty and Contains Relatively Few Products

  • What is the distribution of primary axillary hyperhidrosis pipeline products by stage of development?
  • What are the most common molecular targets for pipeline products?
  • How many companies are currently involved in drug development?
  • What are the current treatment patterns available for primary axillary hyperhidrosis?
  • What are the approved medical devices available in the primary axillary hyperhidrosis market, and how are those competing with the existing drug therapies?
  • What is the impact of hyperhidrosis on the overall quality of life of patients?

Various Barriers will Influence the Primary Axillary Hyperhidrosis Market Over the Forecast Period.

  • What are the barriers for the growth of primary axillary hyperhidrosis market, and what are the recommended steps to overcome these barriers?

Key Reasons to Purchase

  • Understand the current clinical and commercial landscape by considering disease etiology, epidemiology, diagnosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
  • Visualize the primary axillary hyperhidrosis market in terms of dominant therapies for each patient subset. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the primary axillary hyperhidrosis pipeline and stratify pipeline therapies by stage of development, route of administration, molecule type and molecular target.
  • Understand the potential of late-stage therapy, with profile of product that could enter the market over the forecast period, highlighting clinical performance, and competition with other therapies.
  • Predict primary axillary hyperhidrosis market growth in the seven major developed markets, with epidemiological and annual cost of therapy forecasts across the US, Japan, the UK, Germany, France, Spain and Italy.
Note: Product cover images may vary from those shown
2 of 3

1. Executive Summary

2. Disease Overview

  • Classification
  • Etiology
  • Epidemiology
  • Diagnosis

3. Impact of Hyperhidrosis

4. Treatment Patterns and Management

5. Marketed Products and Competitive Assessment

  • Botox - Allergan (Approved)
  • Off-label Products

6. Marketed Medical Devices and Competitive Assessment

  • miraDry - Miramar Labs
  • PrecisionTX - Cynosure

7. Unmet Needs and Gap Analysis

8. Pipeline Analysis

  • Pipeline by Stage of Development and Molecule Type
  • Pipeline by Route of Administration and Molecular Target

9. Pipeline Products

10. Market Size and Forecast (Global, US, Japan, UK, Germany, France, Spain and Italy)

  • Treatment Usage Pattern
  • Annual Cost of Therapy
  • Market Size

11. Challenges for the Market Growth

  • Barriers
  • Steps to Overcome Barriers

12. Appendix

  • Bibliography
Note: Product cover images may vary from those shown
3 of 3